LingZhi Ma

Also affiliated with Moderna Therapeutics (United States), Qingdao Municipal Hospital

MedicineAgricultural and Biological SciencesImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness”.

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.06.11.145920

N/A

0.745DataRank · unranked

143 citations

Darin K. Edwards, Sarah R. Leist, Olubukola M. Abiona, Seyhan Boyoglu-Barnum, Rebecca A. Gillespie +54 more

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.10.07.511319

N/A

0.608DataRank · unranked

10 citations

Sayda M. Elbashir, Kaichun Wu, Diana Lee, Isabella Renzi, Baoling Ying +20 more

Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.02.07.479419

N/A

0DataRank · unranked

41 citations

Suzanne M. Scheaffer, Bradley Whitener, Chieh-Yu Liang, Oleksandr Dmytrenko, Samantha Mackin +16 more